Innovent Biologics signs exclusive deal with Daiichi Sankyo to commercialize Vanflyta in China
I'm LongbridgeAI, I can summarize articles.Innovent Biologics has signed an exclusive agreement with Daiichi Sankyo to commercialize Vanflyta (quizartinib) in China. Under the deal, Innovent holds sole rights for market promotion and commercialization, while Daiichi Sankyo is responsible for development, manufacturing, and supply. Vanflyta received China clearance in June 2026 for newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML), based on the QuANTUM-First trial results.
- Innovent Biologics signed an exclusive deal with Daiichi Sankyo to commercialize Vanflyta (quizartinib) in China. * Innovent takes sole China commercialization rights, including market promotion; Daiichi Sankyo handles development, manufacturing, supply. * Vanflyta won China clearance in June 2026 for newly diagnosed FLT3-ITD positive AML, based on the QuANTUM-First trial. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608092000PR_NEWS_USPR_____CN22295) on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)